Skip to main content

Table 1 Baseline descriptive statistics

From: Effects of a footwear intervention on foot pain and disability in people with gout: a randomised controlled trial

Variable

Footwear intervention group (n = 47)

Control group (n = 47)

Sex, male, n (%)

40 (85%)

43 (91%)

Age, years

62.6 (17.0)

62.4 (13.7)

BMI, kg/m2

30.2 (6.4)

32.0 (7.0)

Ethnicity, n (%)

 NZ European

28 (62%)

26 (57%)

 Pacific

6 (13%)

11 (23%)

 Asian

7 (16%)

5 (11%)

 Māori

4 (9%)

4 (9%)

Gout history, mean (SD)

 Disease duration (years)

12.2 (11.2)

13.6 (12.3)

 Flares prior 3 months

0.7 (0.9)

0.4 (0.7)

 Foot tophus, n (%)

9 (19%)

17 (36%)

 Any tophus, n (%)

13 (28%)

24 (51%)

Serum urate, mmol/L

0.39 (0.13)

0.38 (0.11)

Medications, n (%)

 Urate-lowering therapy

33 (72%)

30 (64%)

 Colchicine

15 (33%)

17 (36%)

 Prednisone

9 (20%)

10 (21%)

 NSAID

12 (27%)

13 (29%)

 Diuretic

8 (18%)

5 (11%)

Medical History, n (%)

 Hypertension

22 (48%)

22 (54%)

 Cardiovascular disease

13 (28%)

11 (24%)

 Type 2 diabetes

7 (15%)

3 (7%)

 Peripheral vascular disease

4 (9%)

3 (7%)

 Peripheral neuropathy

3 (7%)

5 (11%)

  1. BMI body mass index, NSAID non-steroidal anti-inflammatory drug